MX2021011160A - Derivado de heteroarilo, metodo para producirlo y composicion farmaceutica que lo comprende como componente eficaz. - Google Patents
Derivado de heteroarilo, metodo para producirlo y composicion farmaceutica que lo comprende como componente eficaz.Info
- Publication number
- MX2021011160A MX2021011160A MX2021011160A MX2021011160A MX2021011160A MX 2021011160 A MX2021011160 A MX 2021011160A MX 2021011160 A MX2021011160 A MX 2021011160A MX 2021011160 A MX2021011160 A MX 2021011160A MX 2021011160 A MX2021011160 A MX 2021011160A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- effective component
- producing
- treatment
- inhibitory activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190031269 | 2019-03-19 | ||
| KR20190134472 | 2019-10-28 | ||
| PCT/KR2020/095044 WO2020190119A1 (ko) | 2019-03-19 | 2020-03-19 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011160A true MX2021011160A (es) | 2022-02-10 |
Family
ID=72521153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011160A MX2021011160A (es) | 2019-03-19 | 2020-03-19 | Derivado de heteroarilo, metodo para producirlo y composicion farmaceutica que lo comprende como componente eficaz. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12152021B2 (https=) |
| EP (2) | EP4631507A3 (https=) |
| JP (2) | JP7109013B2 (https=) |
| KR (2) | KR102318875B1 (https=) |
| CN (3) | CN114605400B (https=) |
| AU (2) | AU2020240382B2 (https=) |
| BR (1) | BR112021018704B1 (https=) |
| CA (1) | CA3134261A1 (https=) |
| DK (1) | DK3943491T3 (https=) |
| ES (1) | ES3036467T3 (https=) |
| FI (1) | FI3943491T3 (https=) |
| HU (1) | HUE073283T2 (https=) |
| IL (2) | IL299831B2 (https=) |
| MA (1) | MA55380A (https=) |
| MX (1) | MX2021011160A (https=) |
| NZ (2) | NZ790920A (https=) |
| PL (1) | PL3943491T3 (https=) |
| PT (1) | PT3943491T (https=) |
| SG (1) | SG11202110376XA (https=) |
| SI (1) | SI3943491T1 (https=) |
| WO (1) | WO2020190119A1 (https=) |
| ZA (1) | ZA202107889B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| AU2020240382B2 (en) | 2019-03-19 | 2022-08-25 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
| KR20220085735A (ko) * | 2020-12-14 | 2022-06-22 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| EP4335847A1 (en) * | 2021-05-07 | 2024-03-13 | Voronoi Inc. | Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient |
| CN115667251A (zh) * | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
| KR102563834B1 (ko) * | 2021-06-28 | 2023-08-04 | 순천대학교 산학협력단 | 세포자멸사를 유도하는 신규한 화합물 및 이를 포함하는 항암용 조성물 |
| CN117430600A (zh) * | 2022-07-20 | 2024-01-23 | 上海和誉生物医药科技有限公司 | 一种选择性egfr抑制剂及其制备方法和在药学上的应用 |
| KR20250043424A (ko) | 2022-08-05 | 2025-03-28 | 미쓰비시 마테리알 가부시키가이샤 | 절삭 공구 |
| CN120035590A (zh) * | 2022-11-03 | 2025-05-23 | 株式会社沃若诺伊 | Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐 |
| EP4611902A1 (en) | 2022-11-03 | 2025-09-10 | Oric Pharmaceuticals, Inc. | Malonate and glycolate salts of an egfr inhibitor |
| AU2023381004A1 (en) * | 2022-11-15 | 2025-04-10 | Voronoi, Inc. | Heteroaryl derivative compound, and uses thereof |
| MX2025012495A (es) * | 2023-05-05 | 2026-02-03 | Oric Pharmaceuticals Inc | Inhibidor del receptor del factor de crecimiento epidérmico (egfr) para tratamiento de cánceres con mutaciones atípicas del factor de crecimiento epidérmico |
| WO2026080372A1 (en) | 2024-10-07 | 2026-04-16 | Oric Pharmaceuticals, Inc. | Treatment of cancers comprising egfr extracellular and transmembrane mutations |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| WO2006125616A2 (en) | 2005-05-25 | 2006-11-30 | Ingenium Pharmaceuticals Ag | Pyrimidine-based cdk inhibitors for treating pain |
| TW200804364A (en) | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
| EA200901133A1 (ru) | 2007-03-20 | 2010-04-30 | Смитклайн Бичем Корпорейшн | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| JP2011102241A (ja) | 2008-03-04 | 2011-05-26 | Dainippon Sumitomo Pharma Co Ltd | 新規１−アミノカルボニルピペリジン誘導体 |
| KR101906146B1 (ko) | 2009-08-17 | 2018-10-10 | 메모리얼 슬로안-케터링 캔서 센터 | 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법 |
| KR101401664B1 (ko) | 2011-11-15 | 2014-06-11 | 중앙대학교 산학협력단 | 신경줄기세포 분화조절제용 신규 피리미딘-2,4-디아민 유도체 및 이의 의학적 용도 |
| US8871778B2 (en) | 2012-01-20 | 2014-10-28 | Genosco | Substituted pyrimidine compounds and their use as SYK inhibitors |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| WO2014055928A2 (en) | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| EP2970240B1 (en) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| EP3037424B1 (en) | 2013-08-22 | 2017-11-08 | Taiho Pharmaceutical Co., Ltd. | Novel quinoline-substituted compound |
| BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| KR20150047855A (ko) | 2013-10-25 | 2015-05-06 | 한미약품 주식회사 | 단백질 카이네이즈 억제 효과를 갖는 2-사이아노-아크릴아마이드 유도체 |
| EP3143015B1 (en) | 2014-05-13 | 2019-02-20 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN110526912B (zh) | 2014-06-19 | 2023-02-14 | 武田药品工业株式会社 | 用于激酶抑制的杂芳基化合物 |
| CN117069700B (zh) * | 2014-10-11 | 2026-01-30 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
| EP3929190B1 (en) * | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| EP3206691B1 (en) | 2014-10-14 | 2018-09-19 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| CN113563332B (zh) | 2014-12-23 | 2024-12-17 | 达纳－法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
| JP6970081B2 (ja) | 2015-07-16 | 2021-11-24 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | アニリンピリミジン誘導体及びその使用 |
| CN106478607B (zh) | 2015-08-28 | 2019-05-24 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| US10377747B2 (en) | 2015-08-31 | 2019-08-13 | Wuxi Shuangliang Biotechnology Co., Ltd. | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof |
| CN108602809B (zh) | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| EP3399968B8 (en) | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| WO2017156527A1 (en) | 2016-03-11 | 2017-09-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US11352352B2 (en) | 2017-06-13 | 2022-06-07 | Beijing Adamadle Biotechnology Limited Liability Company | Aminopyrimidine compound, preparation method therefor and use thereof |
| CN111093645A (zh) * | 2017-07-05 | 2020-05-01 | Cs制药技术有限公司 | Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂 |
| US11339157B1 (en) | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| TWI798334B (zh) | 2018-01-31 | 2023-04-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｒｂｂ／ｂｔｋ抑制劑 |
| CN108191774B (zh) | 2018-01-31 | 2022-05-24 | 中国药科大学 | 一类杂环化合物、其制备方法和用途 |
| WO2019177374A1 (ko) | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 |
| KR102782739B1 (ko) | 2018-03-13 | 2025-03-20 | 보로노이 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| US12084431B2 (en) | 2018-05-14 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders |
| CN109280048A (zh) | 2018-11-16 | 2019-01-29 | 江西科技师范大学 | 一种含取代苯基丙烯酰胺结构的嘧啶类化合物及其应用 |
| CN109608394A (zh) | 2018-12-03 | 2019-04-12 | 湖南大学 | 氮杂芳胺类化合物的合成方法和氮杂芳胺类化合物 |
| AU2020240382B2 (en) * | 2019-03-19 | 2022-08-25 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
-
2020
- 2020-03-19 AU AU2020240382A patent/AU2020240382B2/en active Active
- 2020-03-19 DK DK20774059.8T patent/DK3943491T3/da active
- 2020-03-19 CN CN202210215237.6A patent/CN114605400B/zh active Active
- 2020-03-19 BR BR112021018704-9A patent/BR112021018704B1/pt active IP Right Grant
- 2020-03-19 ES ES20774059T patent/ES3036467T3/es active Active
- 2020-03-19 KR KR1020200033737A patent/KR102318875B1/ko active Active
- 2020-03-19 CN CN202080022186.4A patent/CN113993866B/zh active Active
- 2020-03-19 EP EP25174837.2A patent/EP4631507A3/en active Pending
- 2020-03-19 PT PT207740598T patent/PT3943491T/pt unknown
- 2020-03-19 JP JP2022504023A patent/JP7109013B2/ja active Active
- 2020-03-19 IL IL299831A patent/IL299831B2/en unknown
- 2020-03-19 PL PL20774059.8T patent/PL3943491T3/pl unknown
- 2020-03-19 CN CN202211226875.4A patent/CN115838369A/zh active Pending
- 2020-03-19 FI FIEP20774059.8T patent/FI3943491T3/fi active
- 2020-03-19 MX MX2021011160A patent/MX2021011160A/es unknown
- 2020-03-19 SI SI202030641T patent/SI3943491T1/sl unknown
- 2020-03-19 NZ NZ790920A patent/NZ790920A/en unknown
- 2020-03-19 NZ NZ781366A patent/NZ781366A/en unknown
- 2020-03-19 HU HUE20774059A patent/HUE073283T2/hu unknown
- 2020-03-19 WO PCT/KR2020/095044 patent/WO2020190119A1/ko not_active Ceased
- 2020-03-19 SG SG11202110376XA patent/SG11202110376XA/en unknown
- 2020-03-19 EP EP20774059.8A patent/EP3943491B1/en active Active
- 2020-03-19 US US17/440,630 patent/US12152021B2/en active Active
- 2020-03-19 MA MA055380A patent/MA55380A/fr unknown
- 2020-03-19 CA CA3134261A patent/CA3134261A1/en active Pending
-
2021
- 2021-09-19 IL IL286471A patent/IL286471B2/en unknown
- 2021-10-15 ZA ZA2021/07889A patent/ZA202107889B/en unknown
- 2021-10-21 KR KR1020210141386A patent/KR102564533B1/ko active Active
- 2021-11-08 US US17/521,711 patent/US11466000B2/en active Active
-
2022
- 2022-07-07 JP JP2022109721A patent/JP7394298B2/ja active Active
- 2022-08-01 AU AU2022211789A patent/AU2022211789B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011160A (es) | Derivado de heteroarilo, metodo para producirlo y composicion farmaceutica que lo comprende como componente eficaz. | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| NZ784224A (en) | Parp1 inhibitors | |
| CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
| CL2020002082A1 (es) | Inhibidores pd-1/pd-l1. | |
| CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| MX2019005737A (es) | Composicion farmaceutica para prevenir o tratar el cancer de cerebro que incluye polimorfocristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo. | |
| MX389683B (es) | Composiciones terapeuticas, combinaciones y metodos de uso | |
| MX2019006622A (es) | Composicion farmaceutica para la prevencion o tratamiento de cancer, que comprende polimorfo cristalino de hexoxido de tetraarsenico. | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| DOP2015000157A (es) | Lactamas fusionadas de arilo y heteroarilo | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| MX377384B (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| ECSP15048555A (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
| MX2018005461A (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| MX2018003301A (es) | Inhibidores de pcna. | |
| MX2021002215A (es) | Derivados de tetrahidropiridopirimidina como moduladores de ahr. | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| CL2024001535A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| MX2017009246A (es) | Farmaco de combinacion. | |
| PE20170193A1 (es) | Derivados de 6-alquinil-piridina | |
| CU20210061A7 (es) | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| CL2020000684A1 (es) | Composiciones, usos y procedimientos para el tratamiento de la infertilidad y la subfertilidad. | |
| CO2024001405A2 (es) | Composiciones y métodos para el tratamiento de cáncer |